Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Main subject
Language
Document Type
Year range
1.
Atmospheric Chemistry and Physics ; 22(21):14243-14252, 2022.
Article in English | ProQuest Central | ID: covidwho-2110593

ABSTRACT

Compared with 2019, measurements of the global growth rate of background (marine air) atmospheric methane rose by 5.3 ppb yr-1 in 2020, reaching 15.0 ppb yr-1. Global atmospheric chemistry models have previously shown that reductions in nitrogen oxide (NOx) emissions reduce levels of the hydroxyl radical (OH) and lengthen the methane lifetime. Acting in the opposite sense, reductions in carbon monoxide (CO) and non-methane volatile organic compound (NMVOC) emissions increase OH and shorten methane's lifetime. Using estimates of NOx, CO, and NMVOC emission reductions associated with COVID-19 lockdowns around the world in 2020 as well as model-derived regional and aviation sensitivities of methane to these emissions, we find that NOx emission reductions led to a 4.8 (3.8 to 5.8) ppb yr-1 increase in the global methane growth rate. Reductions in CO and NMVOC emissions partly counteracted this, changing (reducing) the methane growth rate by -1.4 (-1.1 to -1.7) ppb yr-1 (CO) and -0.5 (-0.1 to -0.9) ppb yr-1 (NMVOC), yielding a net increase of 2.9 (1.7 to 4.0) ppb yr-1. Uncertainties refer to ±1 standard deviation model ranges in sensitivities. Whilst changes in anthropogenic emissions related to COVID-19 lockdowns are probably not the only important factor that influenced methane during 2020, these results indicate that they have had a large impact and that the net effect of NOx, CO, and NMVOC emission changes can explain over half of the observed 2020 methane changes. Large uncertainties remain in both emission changes during the lockdowns and methane's response to them;nevertheless, this analysis suggests that further research into how the atmospheric composition changed over the lockdown periods will help us to interpret past methane changes and to constrain future methane projections.

2.
J Obes Metab Syndr ; 31(3): 277-281, 2022 Sep 30.
Article in English | MEDLINE | ID: covidwho-2025339

ABSTRACT

Background: The mechanism for possible association between obesity and poor clinical outcomes from Coronavirus Disease 2019 (COVID-19) remains unclear. Methods: We analyzed 22,915 adult COVID-19 patients hospitalized from March 2020 to April 2021 to non-intensive care using the American Heart Association National COVID Registry. A multivariable Poisson model adjusted for age, sex, medical history, admission respiratory status, hospitalization characteristics, and laboratory findings was used to calculate length of stay (LOS) as a function of body mass index (BMI). We similarly analyzed 5,327 patients admitted to intensive care for comparison. Results: Relative to normal BMI subjects, overweight, class I obese, and class II obese patients had approximately half-day reductions in LOS (-0.469 days, P<0.01; -0.480 days, P<0.01; -0.578 days, P<0.01, respectively). Conclusion: The model identified a dose-dependent, inverse relationship between BMI category and LOS for COVID-19, which was not seen when the model was applied to critically ill patients.

3.
JCI Insight ; 7(13)2022 07 08.
Article in English | MEDLINE | ID: covidwho-1932894

ABSTRACT

BACKGROUNDProlonged symptoms after SARS-CoV-2 infection are well documented. However, which factors influence development of long-term symptoms, how symptoms vary across ethnic groups, and whether long-term symptoms correlate with biomarkers are points that remain elusive.METHODSAdult SARS-CoV-2 reverse transcription PCR-positive (RT-PCR-positive) patients were recruited at Stanford from March 2020 to February 2021. Study participants were seen for in-person visits at diagnosis and every 1-3 months for up to 1 year after diagnosis; they completed symptom surveys and underwent blood draws and nasal swab collections at each visit.RESULTSOur cohort (n = 617) ranged from asymptomatic to critical COVID-19 infections. In total, 40% of participants reported at least 1 symptom associated with COVID-19 six months after diagnosis. Median time from diagnosis to first resolution of all symptoms was 44 days; median time from diagnosis to sustained symptom resolution with no recurring symptoms for 1 month or longer was 214 days. Anti-nucleocapsid IgG level in the first week after positive RT-PCR test and history of lung disease were associated with time to sustained symptom resolution. COVID-19 disease severity, ethnicity, age, sex, and remdesivir use did not affect time to sustained symptom resolution.CONCLUSIONWe found that all disease severities had a similar risk of developing post-COVID-19 syndrome in an ethnically diverse population. Comorbid lung disease and lower levels of initial IgG response to SARS-CoV-2 nucleocapsid antigen were associated with longer symptom duration.TRIAL REGISTRATIONClinicalTrials.gov, NCT04373148.FUNDINGNIH UL1TR003142 CTSA grant, NIH U54CA260517 grant, NIEHS R21 ES03304901, Sean N Parker Center for Allergy and Asthma Research at Stanford University, Chan Zuckerberg Biohub, Chan Zuckerberg Initiative, Sunshine Foundation, Crown Foundation, and Parker Foundation.


Subject(s)
COVID-19 , COVID-19/complications , Humans , Immunoglobulin G , SARS-CoV-2 , Post-Acute COVID-19 Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL